-
公开(公告)号:US20080090829A1
公开(公告)日:2008-04-17
申请号:US11952608
申请日:2007-12-07
申请人: ERNEST HAMANAKA
发明人: ERNEST HAMANAKA
IPC分类号: A61K31/426 , A61K31/24 , A61K31/4196 , A61K31/427 , A61K31/44 , A61K31/50 , A61P29/00 , A61P9/00 , C07D213/65 , C07D417/10 , C07D277/64 , C07D277/30 , C07D263/32 , C07D249/12 , C07D237/18 , C07D213/70 , C07C311/29 , A61P3/00 , A61P25/00 , A61K31/4412 , A61K31/428 , A61K31/421 , A61K31/423
CPC分类号: C07D277/28 , C07C311/16 , C07C311/17 , C07C311/18 , C07C311/27 , C07C323/49 , C07C2601/14 , C07D213/65 , C07D213/68 , C07D213/70 , C07D237/18 , C07D249/12 , C07D263/32 , C07D263/56 , C07D263/57 , C07D277/66
摘要: The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
摘要翻译: 本发明涉及取代的杂芳基 - 和苯基氨磺酰基化合物,含有这些化合物的药物组合物以及这些化合物如过氧化物酶体增殖物激活受体(PPAR)激动剂的用途。 PPARα激活剂,含有这些化合物的药物组合物以及使用这些化合物来提高某些血浆脂质水平,包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平,如低密度脂蛋白胆固醇和甘油三酸酯,从而治疗 由哺乳动物(包括人类)中低密度脂蛋白胆固醇和/或高水平的低密度脂蛋白胆固醇和甘油三酯(如动脉粥样硬化和心血管疾病)而加剧。 该化合物也可用于治疗反能动物中的负能量平衡(NEB)和相关疾病。
-
公开(公告)号:US20050288340A1
公开(公告)日:2005-12-29
申请号:US11065774
申请日:2005-02-24
申请人: Ernest Hamanaka
发明人: Ernest Hamanaka
IPC分类号: A61K31/18 , A61K31/41 , A61K31/421 , A61K31/423 , A61K31/426 , A61K31/428 , A61K31/44 , A61K31/50 , A61P3/04 , A61P3/06 , A61P3/10 , A61P7/02 , A61P9/10 , A61P9/12 , A61P19/10 , A61P25/28 , A61P29/00 , C07C311/16 , C07C311/17 , C07C311/18 , C07C311/27 , C07C323/49 , C07D213/65 , C07D213/68 , C07D213/70 , C07D237/18 , C07D249/12 , C07D263/32 , C07D263/56 , C07D263/57 , C07D277/22 , C07D277/28 , C07D277/66 , C07D277/70
CPC分类号: C07D277/28 , C07C311/16 , C07C311/17 , C07C311/18 , C07C311/27 , C07C323/49 , C07C2601/14 , C07D213/65 , C07D213/68 , C07D213/70 , C07D237/18 , C07D249/12 , C07D263/32 , C07D263/56 , C07D263/57 , C07D277/66
摘要: The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
摘要翻译: 本发明涉及取代的杂芳基 - 和苯基氨磺酰基化合物,含有这些化合物的药物组合物以及这些化合物如过氧化物酶体增殖物激活受体(PPAR)激动剂的用途。 PPARα激活剂,含有这些化合物的药物组合物以及使用这些化合物来提高某些血浆脂质水平,包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平,如低密度脂蛋白胆固醇和甘油三酸酯,从而治疗 由哺乳动物(包括人类)中低密度脂蛋白胆固醇和/或高水平的低密度脂蛋白胆固醇和甘油三酯(如动脉粥样硬化和心血管疾病)而加剧。 该化合物也可用于治疗反能动物中的负能量平衡(NEB)和相关疾病。
-
公开(公告)号:US20050234099A1
公开(公告)日:2005-10-20
申请号:US11049852
申请日:2005-02-03
申请人: Peter Bertinato , Michel Couturier , Ernest Hamanaka , Marcus Ewing , Ralph Robinson , Derek Tickner
发明人: Peter Bertinato , Michel Couturier , Ernest Hamanaka , Marcus Ewing , Ralph Robinson , Derek Tickner
IPC分类号: A61K31/47 , A61K31/4709 , C07D215/38 , C07D215/48 , C07D401/12 , C07D41/14
CPC分类号: C07D215/48 , C07D401/12
摘要: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
摘要翻译: 本发明涉及式(I)的MTP / Apo-B分泌抑制剂,其中R 1〜R 7,X 1,m和n 如本说明书中所定义,以及包含该化合物的药物组合物,以及该化合物和组合物的使用方法。 本发明的化合物可用于治疗肥胖症和相关疾病,病症或病症。
-
公开(公告)号:US20050228015A1
公开(公告)日:2005-10-13
申请号:US11012139
申请日:2004-12-16
申请人: Ernest Hamanaka , Marcus Kehrli
发明人: Ernest Hamanaka , Marcus Kehrli
IPC分类号: C07C311/21 , C07C311/44 , C07C323/49 , C07D213/75 , C07D215/12 , C07D231/12 , C07D231/56 , C07D233/68 , C07D235/18 , C07D263/32 , C07D263/54 , C07D263/56 , C07D263/57 , C07D271/06 , C07D271/07 , C07D271/10 , C07D271/107 , C07D271/113 , C07D277/24 , C07D277/26 , C07D277/62 , C07D277/66 , C07D285/01 , C07D285/06 , C07D307/79 , C07D333/58 , C07D413/06 , A61K31/47 , A61K31/18 , A61K31/381 , A61K31/4184 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/433
CPC分类号: C07C311/21 , C07C311/44 , C07C323/49 , C07C2601/04 , C07C2601/14 , C07D213/75 , C07D215/12 , C07D231/12 , C07D231/56 , C07D233/68 , C07D263/32 , C07D263/57 , C07D271/06 , C07D271/07 , C07D271/10 , C07D271/107 , C07D271/113 , C07D277/24 , C07D277/26 , C07D277/62 , C07D277/66 , C07D285/01 , C07D285/06 , C07D307/79 , C07D333/58 , C07D413/06
摘要: The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
-
公开(公告)号:US20070093525A1
公开(公告)日:2007-04-26
申请号:US11554351
申请日:2006-10-30
申请人: Peter Bertinato , Michel Couturier , Ernest Hamanaka , Marcus Ewing , Ralph Robinson , Derek Tickner
发明人: Peter Bertinato , Michel Couturier , Ernest Hamanaka , Marcus Ewing , Ralph Robinson , Derek Tickner
IPC分类号: A61K31/4706 , C07D215/38
CPC分类号: C07D215/48 , C07D401/12
摘要: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
摘要翻译: 本发明涉及式(I)的MTP / Apo-B分泌抑制剂,其中R 1〜R 7,X 1,m和n 如本说明书中所定义,以及包含该化合物的药物组合物,以及该化合物和组合物的使用方法。 本发明的化合物可用于治疗肥胖症和相关疾病,病症或病症。
-
公开(公告)号:US20060258723A1
公开(公告)日:2006-11-16
申请号:US11424626
申请日:2006-06-16
申请人: Ernest Hamanaka , Marcus Kehrli
发明人: Ernest Hamanaka , Marcus Kehrli
IPC分类号: A61K31/423 , A61K31/195 , C07D263/60 , C07C311/45
CPC分类号: C07C311/21 , C07C311/44 , C07C323/49 , C07C2601/04 , C07C2601/14 , C07D213/75 , C07D215/12 , C07D231/12 , C07D231/56 , C07D233/68 , C07D263/32 , C07D263/57 , C07D271/06 , C07D271/07 , C07D271/10 , C07D271/107 , C07D271/113 , C07D277/24 , C07D277/26 , C07D277/62 , C07D277/66 , C07D285/01 , C07D285/06 , C07D307/79 , C07D333/58 , C07D413/06
摘要: The present invention is directed at substituted heteroaryl and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator actuator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
摘要翻译: 本发明涉及取代的杂芳基和苯基氨磺酰基化合物,含有这些化合物的药物组合物以及这些化合物如过氧化物酶体增殖物激动剂受体(PPAR)激动剂的用途。 PPARα激活剂,含有这些化合物的药物组合物以及使用这些化合物来提高某些血浆脂质水平,包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平,如低密度脂蛋白胆固醇和甘油三酸酯,从而治疗 由哺乳动物(包括人类)中低密度脂蛋白胆固醇和/或高水平的低密度脂蛋白胆固醇和甘油三酯(如动脉粥样硬化和心血管疾病)而加剧。 该化合物也可用于治疗反能动物中的负能量平衡(NEB)和相关疾病。
-
公开(公告)号:US20060229363A1
公开(公告)日:2006-10-12
申请号:US11424623
申请日:2006-06-16
申请人: Ernest Hamanaka
发明人: Ernest Hamanaka
IPC分类号: A61K31/195 , A61K31/24 , C07C311/45
CPC分类号: C07D277/28 , C07C311/16 , C07C311/17 , C07C311/18 , C07C311/27 , C07C323/49 , C07C2601/14 , C07D213/65 , C07D213/68 , C07D213/70 , C07D237/18 , C07D249/12 , C07D263/32 , C07D263/56 , C07D263/57 , C07D277/66
摘要: The present invention is directed at substituted heteroaryl and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
摘要翻译: 本发明涉及取代的杂芳基和苯基氨磺酰基化合物,含有这些化合物的药物组合物以及这些化合物如过氧化物酶体增殖物激活受体(PPAR)激动剂的用途。 PPARα激活剂,含有这些化合物的药物组合物以及使用这些化合物来提高某些血浆脂质水平,包括高密度脂蛋白胆固醇,并降低某些其他血浆脂质水平如LDL-胆固醇和甘油三酸酯,并因此治疗疾病 在哺乳动物,包括人类中,低水平的HDL胆固醇和/或高水平的LDL-胆固醇和甘油三酸酯如动脉粥样硬化和心血管疾病加剧。 该化合物也可用于治疗反能动物中的负能量平衡(NEB)和相关疾病。
-
公开(公告)号:US20060223851A1
公开(公告)日:2006-10-05
申请号:US11424488
申请日:2006-06-15
申请人: Peter Bertinato , Michel Couturier , Ernest Hamanaka , Marcus Ewing , Ralph Robinson , Derek Tickner
发明人: Peter Bertinato , Michel Couturier , Ernest Hamanaka , Marcus Ewing , Ralph Robinson , Derek Tickner
IPC分类号: A61K31/47
CPC分类号: C07D215/48 , C07D401/12
摘要: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
摘要翻译: 本发明涉及式(I)的MTP / Apo-B分泌抑制剂,其中R 1〜R 7,X 1,m和n 如本说明书中所定义,以及包含该化合物的药物组合物,以及该化合物和组合物的使用方法。 本发明的化合物可用于治疗肥胖症和相关疾病,病症或病症。
-
-
-
-
-
-
-